Physician profile
Shahla Bari
NPI 1487063525
$56,109.25
in general payments reported to CMS, 2019-2025
8 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $59.99 · 2024: $11K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $8,930 · Consulting Fee: $2,205 · Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,100.00 |
| Travel and Lodging | $8,929.79 |
| Consulting Fee | $2,205.00 |
| Food and Beverage | $1,814.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $52,688.84 | 2024-2025 | Welireg, Keytruda |
| Eisai INC. | $2,562.38 | 2024-2025 | |
| Pfizer INC. | $265.43 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $247.25 | 2025 | |
| Telix Pharmaceuticals | $148.58 | 2024 | Illuccix |
| Exelixis INC. | $136.78 | 2024 | Cabometyx |
| Astellas Pharma US INC | $59.99 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahla Bari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.